Search Results - "Laplaige, P"

Primum non nocere: Screening patients for fluoropyrimidine-related toxicity risk: The most effective method by Boisdron-Celle, M., Metges, J., Capitain, O., Faroux, R., Stampfli, C., Ferec, M., Laplaige, P., Lecomte, T., Matysiak-Budnik, T., Senellart, H., Campone, M., Morel, A., Gamelin, E.

Get full text

French Prospective Multi-Center Cohort on The Decision Impact Assessment by Michaud, P, Mouysset, J, Dohollou, N, Laplaige, P, Lafuma, A, Fignon, A

Get full text

PD-032Is there an impact of the number of metastases in the outcome of potentially resectable metastatic colorectal cancer patients receiving bevacizumab-based regimen in 1st line? Results of the PICASSO study by Metges, J-P, Bennouna, J, Rivoire, M, Elias, D, Bonnetain, F, Dourthe, L, Ben Abdelghani, M, Radji, R, Laplaige, P, Petit Laurent, F, Sebastien, K, Telliez, J, Malka, D

Get full text

A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil–epirubicine–cyclophosphamide (FEC100 ) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000) by Delbaldo, C, Serin, D, Mousseau, M, Greget, S, Audhuy, B, Priou, F, Berdah, J.F, Teissier, E, Laplaige, P, Zelek, L, Quinaux, E, Buyse, M, Piedbois, P

“…Abstract Background Standard adjuvant chemotherapy regimens for patients with node positive (N+) breast cancer consisted of anthracycline followed by taxane…”
Get full text

Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study by Piedbois, P., Serin, D., Priou, F., Laplaige, P., Greget, S., Angellier, E., Teissier, E., Berdah, J.-F., Fabbro, M., Valenza, B., Herait, P., Jehl, V., Buyse, M.

“…Background: Adding a taxane to anthracycline-based adjuvant chemotherapy prolongs survival in node-positive patients but optimal dose and schedule remain…”
Get full text

A prospective, observational study describing the haematological response in patients undergoing chemotherapy treated by tri-weekly darbepoetin alfa for anaemia by Ray-Coquard, I., Laplaige, P., Vey, N., Asselain, B., Urbieta, M.

“…Abstract Objective: This prospective, observational study investigated the haematological response to darbepoetin alfa (DA) administered every three weeks for…”
Get full text

Reply to Letter to the editor, by Ishiguro et al. (Ann Oncol) by Piedbois, P., Serin, D., Priou, F., Laplaige, P., Berdah, J.-F., Grenier, J.

Get full text

Multicenter phase II–III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients by Misset, J.-L., Vennin, Ph, Chollet, Ph, Pouillart, P., Laplaige, Ph, Frobert, J. L., Castera, D., Fabro, M., Langlois, D., Cortesi, E., Lucas, V., Gamelin, E., Laadem, A., Otero, J.

“…Summary Purpose: A phase II–III randomised study to compare safety and efficacy of an oxaliplatin/cyclophosphamide (OXAC) combination, vs. the reference…”
Get full text

1885P Discrete Choice Experiment to estimate physicians’ Preferences in terms of G-CSF use for febrile neutropenia primary and secondary prophylaxis by Scotté, F., Antoine, E-C., Simon, H., Texier, N., Laplaige, P., Chouaid, C.

Get full text

5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. final results of a randomised trial in metastatic colorectal cancer by Rougier, Ph, Paillot, B., LaPlanche, A., Morvan, F., Seitz, J.F., Rekacewicz, C., Laplaige, P., Jacob, J., Grandjouan, S., Tigaud, J.M., Fabri, M.C., Luboinski, M., Ducreux, M.

“…The aim of this Phase III, balanced randomised trial was to compare continuous intravenous infusion (CVI) of 5-FU with bolus (B) administration for metastatic…”
Get full text

Abstract P6-07-28: The 21-gene assay in the decision impact assessment of ER+, HER2- Breast cancer: A French real life prospective study by Gligorov, J, Dohollou, N, Mouysset, JL, Laplaige, P, Fignon, A, Lafuma, A, Michaud, P

“…Abstract BACKGROUND: Tumour gene expression analysis is useful in predicting adjuvant chemotherapy benefit in breast cancer (BC). The 21-gene assay test is…”
Get full text

549PImpact of concomitant medications on disease free survival (DFS) and overall survival (OS) in patients from the PETACC8 study by Clémence, B, Taieb, J, Boulin, M, Malicot, K Le, Dourthe, L M, Avisse, B, Laplaige, P, Borel, C, Arsene, D, Kikolski, F, Denis, B, Geoffroy, P, Coriat, R, Piot, G, Lepage, C

“…Abstract Background Impact of comedications and comorbidities upon OS isn’t well described in cancer patients (pts). We aimed to evaluate their impacts on DFS…”
Get full text

Impact of concomitant medications on disease free survival (DFS) and overall survival (OS) in patients from the PETACC8 study by Clémence, B., Taieb, J., Boulin, M., Malicot, K Le, Dourthe, L.M., Avisse, B., Laplaige, P., Borel, C., Arsene, D., Kikolski, F., Denis, B., Geoffroy, P., Coriat, R., Piot, G., Lepage, C.

Get full text

549P - Impact of concomitant medications on disease free survival (DFS) and overall survival (OS) in patients from the PETACC8 study by Clémence, B., Taieb, J., Boulin, M., Malicot, K Le, Dourthe, L.M., Avisse, B., Laplaige, P., Borel, C., Arsene, D., Kikolski, F., Denis, B., Geoffroy, P., Coriat, R., Piot, G., Lepage, C.

“…Impact of comedications and comorbidities upon OS isn’t well described in cancer patients (pts). We aimed to evaluate their impacts on DFS and OS on pts…”
Get full text

P-216Primum non nocere: Screening patients for fluoropyrimidine-related toxicity risk: The most effective method by Boisdron-Celle, M, Metges, J, Capitain, O, Faroux, R, Stampfli, C, Ferec, M, Laplaige, P, Lecomte, T, Matysiak-Budnik, T, Senellart, H, Campone, M, Morel, A, Gamelin, E

Get full text

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials by Barbier, Emilie, François, Eric, Michel, Pierre, Rougier, Philippe, Seitz, Jean-François, Aouakli, A., Bedjaoui, A., Botton, A., Cadier-Lagnes, A., Hollebecque, A., Lemaire, A., Marre, A., Villing, A.L., Denis, B., Becht, C., Bineau, C., Borel, C., Buffet, C., Cornila, C., Couffon, C., Locher, C., Rebischung, C., Sarda, C., Auby, D., Baudet-Klepping, D., Besson, D., Cleau, D., Festin, D., Genet, D., Peré-Vergé, D., Pillon, D., Smith, D., Dorval Danquechin, E., Maillard, E., Mitry, E., Suc, E., Zrihen, E., Pariente, E.A., Dewaele, F., Di Fiore, F., Husseini, F., Kikolski, F., Petit-Laurent, F., Zerouala-Boussaha, F., Caroli-Bosc, F.X., Boilleau-Jolimoy, G., Medinger, G., Graber, I., Charneau, J., Cretin, J., Deguiral, J., Lacourt, J., Meunier, J., Vincent, J., Volet, J., Barbare, J.C., Paitel, J.F., Raoul, J.L., Gornet, J.M., Aucouturier, J.P., Barbieux, J.P., Plachot, J.P., Ramain, J.P., Spano, J.P., Bouhier-Leporrier, K., Cany, L., Rob, L., Baconnier, M., Benchalal, M., Combe, M., Duluc, M., Giovannini, M., Mabro, M., Ramdani, M., Tissot, M., Clavero-Fabri, M.C., Gouttebel, M.C., Kaminsky, M.C., Stremsdoerfer, N., Burtin, P., Cassan, P., Claudé, P., Couzigou, P., Geoffroy, P., Godeau, P., Hammel, P., Novello, P., Prost, P., Ruszniewski, P., Texereau, P., Coriat, R., Nasca, S., Fratte, S.P., Mansourbakht, T., Walter, T., Derias, V., Jestin Le Tallec, V., Sebbagh, V., Adhoute, X., Becouarn, Y.

“…Previous studies showed that high and low body mass index (BMI) was associated with worse prognosis in early-stage colorectal cancer (CRC), and low BMI was…”
Get full text

The 21-Gene Assay In The Decision Impact Assessment of ER+, HER2- Breast Cancer: A French Real Life Prospective Study by Mouysset, J, Laplaige, P, Fignon, A, Jallais, L, Lafuma, A, Michaud, P, Dohollou, N, Gligorov, J

Get full text

PMD5 - The 21-Gene Assay In The Decision Impact Assessment of ER+, HER2- Breast Cancer: A French Real Life Prospective Study by Mouysset, J, Laplaige, P, Fignon, A, Jallais, L, Lafuma, A, Michaud, P, Dohollou, N, Gligorov, J

Get full text

PMD2 - French Prospective Multi-Center Cohort on The Decision Impact Assessment by Michaud, P., Mouysset, J., Dohollou, N., Laplaige, P., Lafuma, A., Fignon, A.

Get full text

Bevacizumab combined with 1st line chemotherapy in elderly patients (≥75 years-old) with metastatic colorectal cancer - Interim results according to the chemotherapy regimen (CASSIOPEE) by Mineur, L., Francois, E., Kim, S., Burki, F., Laplaige, P., Gourgou, S., Rollot-Trad, F., Telliez, J., Gandon, S., Smith, D.

Get full text